The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Overall survival by IDH2 mutant allele in late-stage R/R AML patients enrolled in IDHENTIFY
Stéphane de Botton, MD, PhD, Gustave Roussy Institute, Paris, France, discusses a subgroup analysis of the IDHENTIFY study (NCT02577406) where overall survival (OS) by IDH2 mutant allele in patients with late-stage mutant IDH2 relapsed/refractory (R/R) acute myeloid leukemia (AML) is evaluated. IDHENTIFY is a Phase III study investigating enasidenib compared to conventional care regimens in R/R AML. In this update, mutational burden and co-mutational profiles differed between patients with mIDH2-R140 and mIDH2-R172 R/R AML. Enasidenib improved survival outcomes for patients with IDH2-R172 mutations, with median OS and 1-year survival rate approximately double those in the standard of care arm. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
